449 related articles for article (PubMed ID: 20207952)
1. Hepatic metabolism and transporter gene variants enhance response to rosuvastatin in patients with acute myocardial infarction: the GEOSTAT-1 Study.
Bailey KM; Romaine SP; Jackson BM; Farrin AJ; Efthymiou M; Barth JH; Copeland J; McCormack T; Whitehead A; Flather MD; Samani NJ; Nixon J; Hall AS; Balmforth AJ;
Circ Cardiovasc Genet; 2010 Jun; 3(3):276-85. PubMed ID: 20207952
[TBL] [Abstract][Full Text] [Related]
2. Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care.
DeGorter MK; Tirona RG; Schwarz UI; Choi YH; Dresser GK; Suskin N; Myers K; Zou G; Iwuchukwu O; Wei WQ; Wilke RA; Hegele RA; Kim RB
Circ Cardiovasc Genet; 2013 Aug; 6(4):400-8. PubMed ID: 23876492
[TBL] [Abstract][Full Text] [Related]
3. A randomized, controlled trial of simvastatin versus rosuvastatin in patients with acute myocardial infarction: the Secondary Prevention of Acute Coronary Events--Reduction of Cholesterol to Key European Targets Trial.
Hall AS; Jackson BM; Farrin AJ; Efthymiou M; Barth JH; Copeland J; Bailey KM; Romaine SP; Balmforth AJ; McCormack T; Whitehead A; Flather MD; Nixon J;
Eur J Cardiovasc Prev Rehabil; 2009 Dec; 16(6):712-21. PubMed ID: 19745745
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetic determinants of statin-induced reductions in C-reactive protein.
Chu AY; Guilianini F; Barratt BJ; Nyberg F; Chasman DI; Ridker PM
Circ Cardiovasc Genet; 2012 Feb; 5(1):58-65. PubMed ID: 22230323
[TBL] [Abstract][Full Text] [Related]
5. Achievement of LDL-cholesterol goal with statins after an st segment elevation myocardial infarction.
Tungsubutra W; Phongtuntakul B
J Med Assoc Thai; 2015 Feb; 98(2):129-36. PubMed ID: 25842792
[TBL] [Abstract][Full Text] [Related]
6. Impact of CYP2D6, CYP3A5, CYP2C19, CYP2A6, SLCO1B1, ABCB1, and ABCG2 gene polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid.
Choi HY; Bae KS; Cho SH; Ghim JL; Choe S; Jung JA; Jin SJ; Kim HS; Lim HS
Pharmacogenet Genomics; 2015 Dec; 25(12):595-608. PubMed ID: 26367500
[TBL] [Abstract][Full Text] [Related]
7. Lack of association between SLCO1B1 polymorphisms and clinical myalgia following rosuvastatin therapy.
Danik JS; Chasman DI; MacFadyen JG; Nyberg F; Barratt BJ; Ridker PM
Am Heart J; 2013 Jun; 165(6):1008-14. PubMed ID: 23708174
[TBL] [Abstract][Full Text] [Related]
8. Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males.
Zhang W; Yu BN; He YJ; Fan L; Li Q; Liu ZQ; Wang A; Liu YL; Tan ZR; Fen-Jiang ; Huang YF; Zhou HH
Clin Chim Acta; 2006 Nov; 373(1-2):99-103. PubMed ID: 16784736
[TBL] [Abstract][Full Text] [Related]
9. ABCB1 gene polymorphisms, ABCB1 haplotypes and ABCG2 c.421c > A are determinants of inter-subject variability in rosuvastatin pharmacokinetics.
Zhou Q; Ruan ZR; Yuan H; Xu DH; Zeng S
Pharmazie; 2013 Feb; 68(2):129-34. PubMed ID: 23469685
[TBL] [Abstract][Full Text] [Related]
10. The Effect of Genetic Polymorphisms in SLCO2B1 on the Lipid-Lowering Efficacy of Rosuvastatin in Healthy Adults with Elevated Low-Density Lipoprotein.
Kim TE; Shin D; Gu N; Jung BH; Kim J; Cho YM; Yu KS; Cho JY
Basic Clin Pharmacol Toxicol; 2017 Sep; 121(3):195-201. PubMed ID: 28627804
[TBL] [Abstract][Full Text] [Related]
11. Effects of polymorphisms in ABCG2, SLCO1B1, SLC10A1 and CYP2C9/19 on plasma concentrations of rosuvastatin and lipid response in Chinese patients.
Lee HK; Hu M; Lui SSh; Ho CS; Wong CK; Tomlinson B
Pharmacogenomics; 2013 Aug; 14(11):1283-94. PubMed ID: 23930675
[TBL] [Abstract][Full Text] [Related]
12. Simvastatin pharmacokinetics in healthy Chinese subjects and its relations with CYP2C9, CYP3A5, ABCB1, ABCG2 and SLCO1B1 polymorphisms.
Zhou Q; Ruan ZR; Jiang B; Yuan H; Zeng S
Pharmazie; 2013 Feb; 68(2):124-8. PubMed ID: 23469684
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of a potential transporter-mediated drug interaction between rosuvastatin and pradigastat, a novel DGAT-1 inhibitor.
Kulmatycki K; Hanna I; Meyers D; Salunke A; Movva A; Majumdar T; Natrillo A; Vapurcuyan A; Rebello S; Sunkara G; Chen J
Int J Clin Pharmacol Ther; 2015 May; 53(5):345-55. PubMed ID: 25740267
[TBL] [Abstract][Full Text] [Related]
14. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
15. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
Strandberg TE; Feely J; Sigurdsson EL;
Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
[TBL] [Abstract][Full Text] [Related]
16. Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia.
Yamakawa Y; Hamada A; Nakashima R; Yuki M; Hirayama C; Kawaguchi T; Saito H
Ther Drug Monit; 2011 Apr; 33(2):244-50. PubMed ID: 21311410
[TBL] [Abstract][Full Text] [Related]
17. Loss of function polymorphisms in SLCO1B1 (c.521T>C, rs4149056) and ABCG2 (c.421C>A, rs2231142) genes are associated with adverse events of rosuvastatin: a case-control study.
Merćep I; Radman I; Trkulja V; Božina T; Šimičević L; Budimir E; Ganoci L; Božina N
Eur J Clin Pharmacol; 2022 Feb; 78(2):227-236. PubMed ID: 34668025
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial.
McKenney JM; Jones PH; Adamczyk MA; Cain VA; Bryzinski BS; Blasetto JW;
Curr Med Res Opin; 2003; 19(8):689-98. PubMed ID: 14687438
[TBL] [Abstract][Full Text] [Related]
19. Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II.
Ballantyne CM; Bertolami M; Hernandez Garcia HR; Nul D; Stein EA; Theroux P; Weiss R; Cain VA; Raichlen JS
Am Heart J; 2006 May; 151(5):975.e1-9. PubMed ID: 16644314
[TBL] [Abstract][Full Text] [Related]
20. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial.
Ridker PM; Danielson E; Fonseca FA; Genest J; Gotto AM; Kastelein JJ; Koenig W; Libby P; Lorenzatti AJ; Macfadyen JG; Nordestgaard BG; Shepherd J; Willerson JT; Glynn RJ;
Lancet; 2009 Apr; 373(9670):1175-82. PubMed ID: 19329177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]